Patents Assigned to Vertex Pharmaceuticals
  • Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
    Patent number: 8410274
    Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 2, 2013
    Assignee: Vertex Pharmaceuticals
    Inventors: Patricia Hurter, William Rowe, Christopher Ryan Young, Adriana Costache, Patrick R. Connelly, Mariusz Krawiec, Yuchuan Gong, Yushi Feng, Martin Trudeau
  • Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 8404849
    Abstract: The present invention relates to the process for producing modulators of cystic fibrosis transmembrane conductance regulator (CFTR).
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 26, 2013
    Assignee: Vertex Pharmaceuticals
    Inventors: Lifang Sun, Khisal Ahmed Alvi, Caroline Joyce Decker, Yongmin Li
  • Process for preparing azabicyclic compounds
    Patent number: 8404865
    Abstract: The present invention relates to a process for preparing azabicyclic compounds that are useful intermediates for synthesizing pharmaceutical compounds or salts thereof.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: March 26, 2013
    Assignee: Vertex Pharmaceuticals
    Inventors: Narendra Bhalchandra Ambhaikar, Brian Richard Bear, Lev T. D. Fanning, Robert Hughes, Benjamin Littler
  • SODIUM CHANNEL PROTEIN TYPE III ALPHA-SUBUNIT SPLICE VARIANT
    Publication number: 20090264623
    Abstract: The present invention is directed to a splice variant of a human sodium channel alpha subunit and methods and compositions for making and using the same.
    Type: Application
    Filed: April 1, 2009
    Publication date: October 22, 2009
    Applicant: VERTEX PHARMACEUTICALS
    Inventors: Kenneth J. McCormack, Christopher D. Raj
  • HCV NS3-NS4 Protease Resistance Mutants
    Publication number: 20090191555
    Abstract: The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.
    Type: Application
    Filed: November 17, 2008
    Publication date: July 30, 2009
    Applicant: VERTEX PHARMACEUTICALS
    Inventors: CHAO LIN, KAI LIN
  • Biomarkers for Monitoring Impdh Pathway Inhibition
    Publication number: 20080318803
    Abstract: The present invention is directed to methods for ameliorating reproductive disorders. More specifically, the present invention describes methods and compositions for using IL-17 in the treatment of various infertility-related defects.
    Type: Application
    Filed: May 27, 2005
    Publication date: December 25, 2008
    Applicant: VERTEX PHARMACEUTICALS
    Inventors: Jugnu Jain, Matthew W. Harding, Ravi Ramachandran, Martyn Botfield
  • Hcv Ns3-Ns4a Protease Inhibition
    Publication number: 20080267915
    Abstract: The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: September 30, 2005
    Publication date: October 30, 2008
    Applicant: Vertex Pharmaceuticals
    Inventors: Chao Lin, William P. Taylor